Refine Search

New Search

Advanced search

Journal OncoTargets and Therapy

-
3,494 articles
Page of 350
Articles per Page
by
Published: 18 January 2019
OncoTargets and Therapy; doi:10.2147/ott

Abstract:An international, peer-reviewed journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. In terms of therapy, palliative care is also included as part of the overall patient care process.
Hongzhi Zhang, Huijuan Jiang, Huixiang Zhang, Juncai Liu, Xigang Hu, Lei Chen
Published: 15 January 2019
OncoTargets and Therapy, Volume 12, pp 599-607; doi:10.2147/ott.s187881

Abstract:MiR-4262, low level of which predicts poor prognosis, targets proto-oncogene CD163 to suppress cell proliferation and invasion in gastric cancer Hongzhi Zhang, Huijuan Jiang, Huixiang Zhang, Juncai Liu, Xigang Hu, Lei Chen Department of Radiotherapy, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China Background: miR-4262 was identified as a tumor promoter in several cancers, but its exact role in gastric carcinoma is still largely unknown. Methods: The expression of miR-4262 was detected in gastric cancer tissues. Different concentrations of miR-4262 mimic and miR-4262 antagomir were respectively transfected into primary gastric carcinoma cells. After incubation for 72 h, the overexpression efficiencies were confirmed by qPCR, cell proliferation was detected with the CCK-8 assay, cell apoptosis was detected by using the PI/Annexin V Cell Apoptosis Kit, and cell invasion was detected with the Transwell invasion assay. The molecular mechanisms underlying the action of miR-4262 in gastric carcinoma cells were also explored. Results: In this study, we found that miR-4262 was significantly downregulated in gastric tissue from gastric cancer patients compared with that from the control group. Moreover, the level of miR-4262 was significantly lower in advanced gastric carcinoma. Additionally, lower level of miR-4262 was correlated with poorer prognosis and lower survival rate in gastric cancer patients. Then, different concentrations of miR-4262 mimic and miR-4262 antagomir were transfected into primary gastric carcinoma cells, respectively. The results showed that miR-4262 mimic suppressed proliferation and invasion and promoted cell apoptosis in a dose-dependent manner in gastric carcinoma cells. In contrast, miR-4262 antagomir increased proliferation and invasion and decreased cell apoptosis in a dose-dependent manner in gastric carcinoma cells. Furthermore, miR-4262 could directly target and suppress the expression of the proto-oncogene CD163. Conclusion: Our findings indicate that lower level of miR-4262 predicts poorer prognosis in gastric patients, and miR-4262 can target proto-oncogene CD163 to suppress gastric cancer cell proliferation and invasion. Keywords: miR-4262, gastric carcinoma, prognosis, proliferation and invasion, CD163
Changqing Fu, Xiaojue Zhu, Peiqi Xu, Yonghao Li
Published: 15 January 2019
OncoTargets and Therapy, Volume 12, pp 609-617; doi:10.2147/ott.s182806

Abstract:Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy Changqing Fu,1 Xiaojue Zhu,2 Peiqi Xu,2 Yonghao Li2 1Clinical Laboratory, Zhangjiagang Fifth People’s Hospital, Suzhou University, Suzhou, Jiangsu 215621, People’s Republic of China; 2Clinical Laboratory, Zhangjiagang First People’s Hospital, Suzhou University, Suzhou, Jiangsu 215600, People’s Republic of China Background: Effectiveness of clinical therapy such as chemotherapy for solid tumors is limited by acquired drug resistance and side effects. Available antitumor immunity methods showed promising prospect of cancer therapy. However, more drug targets for boosting antitumor immunity still need to be explored and selective and effective compounds are yet to be developed. Purpose: To study the effect and possible mechanism of compound P5091, a selective USP7 inhibitor, on CT26 xenografts growth in mice. Materials and methods: CT26 xenografts model was employed to examine the anti-tumor effect of P5091. RT-PCR and ELISA analysis were used to detect the level of IFN-γ, TNF-α and IL-10 in tumor tissue and serum, respectively. IFN-γ expression in CD4+ and CD8+ T cells was analyzed by intracellular stain. The level of FOXP3 in Treg cells was confirmed by intracellular stain and western blotting. Results: Compound P5091, a selective USP7 inhibitor, was found to inhibit CT26 xenografts growth in mice, which is comparable to the effect of Anti-PD-1 antibody. RT-PCR analysis showed that P5091 treatment decreased IL-10 mRNA level in tumor tissue while elevated mRNA level of IFN-γ and TNF-α. Moreover, ELISA analysis manifested decreased of IL-10 and elevation of IFN-γ and TNF-α in serum from tumor bearing mice. Intracellular stain showed increased IFN-g expression both in CD4+ and CD8+ T cells after P5091 treatment. Furthermore, P5091 treatment caused FOXP3 loss in Treg cells decreased the proportion of Treg cells in tumor bearing mice. Conclusion: Our study here showed that P5091 may be a candidate for cancer immunotherapy. Keywords: USP7, Treg, antitumor immunity, colon cancer
Yun Huang, Zeyu Zhang, Yufan Zhou, Jiajin Yang, Kuan Hu, Zhiming Wang
Published: 11 January 2019
OncoTargets and Therapy, Volume 12, pp 541-548; doi:10.2147/ott.s187357

Abstract:Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? Yun Huang, Zeyu Zhang, Yufan Zhou, Jiajin Yang, Kuan Hu, Zhiming Wang Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China Objective: Microvascular invasion (MVI) has been proved to be an independent risk factor for the recurrence of HCC. If promptly treated, the recurrence rate can be reduced and the total survival time can be prolonged. The aim of this study is to analyze the effect of sorafenib on the clinical outcomes in HCC patients with MVI after curative hepatectomy.Methods: HCC patients who underwent hepatectomy and were pathologically diagnosed with MVI were retrospectively analyzed. Patients were divided into sorafenib group and control group. Sorafenib 400 mg, twice daily, was administered orally after surgery in the sorafenib group. The recurrence-free survival (RFS) and overall survival (OS) were observed during follow-up, and associated factors were analyzed using univariate and multivariate COX regression.Results: There was no significant difference in demographics, clinical staging, and tumor index between sorafenib group (16 patients) and control group (33 matched patients). The RFS and OS were both longer in the sorafenib group, and the 3-years RFS rates of the sorafenib group and control group were 56.3% (9 of 16) and 24.2% (8 of 33), respectively (P=0.027). The 3-year OS rate of the sorafenib group was 81.3% (13 of 16), which was significantly higher than that of the control group (39.4%, P=0.006). The results of multivariate COX regression indicated that treatment with sorafenib was an independent associated factor for RFS and OS.Conclusion: We believe that using sorafenib therapy after curative hepatectomy in HCC patients with MVI is effective and beneficial as it can reduce recurrence and prolong the survival time. Keywords: sorafenib, hepatocellular carcinoma, microvascular invasion, hepatectomy, survival rate
Yunqiang Nie, Hongjun Liu, Xiao Tan, Hui Wang, Fuzhou Li, Cuiyun Li, Ping Han, Xin Lyv, Xinyi Xu, Miao Guo
Published: 10 January 2019
OncoTargets and Therapy, Volume 12, pp 519-526; doi:10.2147/ott.s184217

Abstract:Correlation between high-resolution computed tomography lung nodule characteristics and EGFR mutation in lung adenocarcinomas Yunqiang Nie,1 Hongjun Liu,2 Xiao Tan,3 Hui Wang,1 Fuzhou Li,4 Cuiyun Li,1 Ping Han,1 Xin Lyv,1 Xinyi Xu,1 Miao Guo5 1Department of Respiratory Medicine, Linyi People’s Hospital, Linyi 276000, China; 2Department of Internal Medicine, 120 Emergency Command Center of Linyi City, Linyi 276002, China; 3Department of Pathology, Linyi People’s Hospital, Linyi 276000, China; 4Department of Radiology, Linyi People’s Hospital, Linyi 276000, China; 5Department of Geriatrics, Linyi People’s Hospital, Linyi 276000, China Background: The aim of this study was to investigate the correlation of EGFR mutation on the high-resolution computed tomography (HRCT) features in lung adenocarcinoma. Patients and methods: A total of 121 patients were diagnosed with lung adenocarcinoma from January 2014 to December 2016. The correlation of indexes (gender, age, tumor diameter, and EGFR mutation) was analyzed based on the HRCT characteristics of lung adenocarcinoma. Results: There were 73 cases of EGFR mutation and 48 cases of wild-type EGFR. One hundred and three cases had pleural indentation that was significant in patients with EGFR mutation than those with wild-type EGFR (P=0.038). Forty-two out of 121 cases exhibited the bronchus cutoff sign. Patients with EGFR mutation were likely to develop the bronchus cutoff sign (P=0.017). Sixty-one out of 121 cases exhibited the lobulation sign, which was significant in patients with EGFR mutation than those with wild-type EGFR (P0.05). Age and gender did not vary significantly in the lobulation sign (P>0.05). Conclusion: HRCT characteristics such as pleural indentation, bronchus cutoff sign, and lobulation sign in lung adenocarcinoma with EGFR mutation were significantly greater than those with wild-type EGFR; however, further study is essential in determining the predictive ability of computed tomography (CT) for EGFR mutations in lung adenocarcinoma. Keywords: computed tomography, EGFR mutation, lung adenocarcinoma, pleural traction, bronchus cutoff sign
Hui-Min Chen, Ge Feng
Published: 8 January 2019
OncoTargets and Therapy, Volume 12, pp 449-455; doi:10.2147/ott.s186642

Abstract:Nodal staging score and adequacy of nodal staging Hui-Min Chen, Ge Feng Nanjing Jiangbei People’s Hospital, Nanjing 220000, People’s Republic of China Aims: The number of lymph nodes (LNs) excised in patients with pathologic N0 is limited, and it is very likely that there will be recessive node disease after surgery, so they are at risk of understaging. The purpose of the present study is to develop a nodal staging score (NSS) in a mathematical way to assess the likelihood that a pathologic N0 gastric cancer (GCa) patient has, indeed, no occult nodal disease after surgery. Patients and methods: A total of 14,033 stage I–III GCa patients were identified from Surveillance, Epidemiology and End Results database for analysis. A beta-binomial model was fitted to calculate the probability of missing a nodal disease. This probability is then used to calculate the NSS. Results: The probability of missing a nodal disease is decreased with increasing LNs examined across all pT stages. Seven and 24 LNs removed and examined was enough for an NSS of 90% in pT1 and pT2 patients, respectively, ensuring a high confidence of correct nodal negative classification. Twenty-three and 31 LNs examined in pT3 and pT4 patients could also maintain the NSS at 80%, respectively. NSS had a significant impact on patients’ survival across all pT stages (all Ps <0.0001). Conclusion: The probability that GCa patients are free of true nodal disease could be provided by NSS-based prediction, which is conducive to postoperative decision and survival surveillance. In addition, NSS can define a subtle standard on how many LNs examined are enough for adequate staging dependent on pT stages. However, at least 16 LNs examined is the standard recommendation to date. Keywords: gastric cancer, nodal-negative classification, adequate staging, prognosis
Chaosen Yue, Yaoyao Ren, Hua Ge, Chaojie Liang, Yingchen Xu, Guangming Li, Jixiang Wu
Published: 1 January 2019
OncoTargets and Therapy, Volume 12, pp 561-576; doi:10.2147/ott.s188913

Abstract:Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma Chaosen Yue,1 Yaoyao Ren,2 Hua Ge,1 Chaojie Liang,1 Yingchen Xu,1 Guangming Li,1 Jixiang Wu1 1Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China Background: Hepatocellular carcinoma (HCC) is an extremely common malignant tumor with worldwide prevalence. The aim of this study was to identify potential prognostic genes and construct a competing endogenous RNA (ceRNA) regulatory network to explore the mechanisms underlying the development of HCC. Methods: Integrated analysis was used to identify potential prognostic genes in HCC with R software based on the GSE14520, GSE17548, GSE19665, GSE29721, GSE60502, and the Cancer Genome Atlas databases. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway-enrichment analyses were performed to explore the molecular mechanisms of potential prognostic genes. Differentially expressed miRNAs (DEMs) and lncRNAs (DELs) were screened based on the Cancer Genome Atlas database. An lncRNA–miRNA–mRNA ceRNA regulatory network was constructed based on information about interactions derived from the miRcode, TargetScan, miRTarBase, and miRDB databases. Results: A total of 152 potential prognostic genes were screened that were differentially expressed in HCC tissue and significantly associated with overall survival of HCC patients. There were 13 key potential prognostic genes in the ceRNA regulatory network: eleven upregulated genes (CCNB1, CEP55, CHEK1, EZH2, KPNA2, LRRC1, PBK, RRM2, SLC7A11, SUCO, and ZWINT) and two downregulated genes (ACSL1 and CDC37L1) whose expression might be regulated by eight DEMs and 61 DELs. Kaplan–Meier curve analysis showed that nine DELs (AL163952.1, AL359878.1, AP002478.1, C2orf48, C10orf91, CLLU1, CLRN1-AS1, ERVMER61-1, and WARS2-IT1) in the ceRNA regulatory network were significantly associated with HCC-patient prognoses. Conclusion: This study identified potential prognostic genes and constructed an lncRNA–miRNA–mRNA ceRNA regulatory network of HCC, which not only has important clinical significance for early diagnoses but also provides effective targets for HCC treatments and could provide new insights for HCC-interventional strategies. Keywords: hepatocellular carcinoma, prognostic gene, ceRNA
Xianwei Li, Bo Chen, Decai Chi, Yingnan Zhang, Weiliang Jiang
Published: 1 January 2019
OncoTargets and Therapy, Volume 12, pp 423-432; doi:10.2147/ott.s181914

Abstract:LncRNA CASC9 regulates cell migration and invasion in hemangioma endothelial cells by targeting miR-125a-3p/Nrg1 Xianwei Li, Bo Chen, Decai Chi, Yingnan Zhang, Weiliang Jiang Department of Vascular Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, People’s Republic of China Background: Despite being one of the most common benign tumors, the prevalence and pathogenesis of hemangiomas (HAs) are poorly understood. We aimed to identify the biological role of the long non-coding RNA (lncRNA) CASC9 in the HA-derived endothelial cell (HDECs) phenotype as well as elucidate the mechanism involved. Methods: The expression of CASC9 was identified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). the effect of CASC9 on cell proliferation, migration and invasion of HDECs were examined by CCK8, wound healing, and transwell assay, respectively. Bioinformatics analysis and a luciferase reporter assay were utilized to investigated the mechanisms involved. The in vivo tumorigenesis capability of CASC9 on HA was also evaluated. Results: The expression of CASC9 was significantly elevated in HA tissue compared to normal tissue. Down-regulation of CASC9 inhibited proliferation, migration, and invasion of HDECs. The translation of cyclinD1, N-cadherin, Twist, and MMP2 was also decreased by CASC9 knockdown treatment. Furthermore, CASC9 over-expression exerted the opposite effect of proliferation, migration, and invasion of HDECs. We also found that CASC9 interacts with miR-125a-3p/Nrg1 to regulate cellular functions. Interestingly, miR-125a-3p can reverse the effect of CASC9 on proliferation, migration, and invasion of HDECs. Together, the clinical data showed that CASC9 expression is negatively correlated with miR-125a-3p expression and positively correlated with Nrg1 expression. CASC9 also exerted anti-tumorigenesis capability in vivo. Conclusion: Our study indicates that CASC9 accelerates cell growth and invasion of HDECs and provides new insights for the diagnosis and molecular therapy of HA. Keywords: CASC9, cell migration, invasion, hemangioma, miR-125a-3p, Nrg1
Zhan Wang, Wei-Ping Dai, Yuan-Sheng Zang
Published: 1 January 2019
OncoTargets and Therapy, Volume 12, pp 443-447; doi:10.2147/ott.s180845

Abstract:Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report Zhan Wang*, Wei-Ping Dai*, Yuan-Sheng Zang Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China *These authors contributed equally to this work Background: Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The Southwest Oncology Group (SWOG) 1406 study evaluated the efficacy of vemurafenib in combination with irinotecan and cetuximab for simultaneous inhibition of epidermal growth factor receptor (EGFR) and BRAF in patients with BRAFV600E-mutated mCRC. Although the combination achieved higher progression-free survival (PFS) and disease control rates (DCRs), there was no complete response (CR) for the drug combination. In this case report, we report the complete recession of metastasis in a patient treated with irinotecan, cetuximab, vemurafenib, and 5-fluorouracil.Case presentation: A 44-year-old male patient with hepatitis B was diagnosed with right-sided colon adenocarcinoma. He was treated with capecitabine plus oxaliplatin as postoperative adjuvant chemotherapy for eight cycles with a disease-free survival (DFS) of 1 year before the emergence of peritoneal and pelvic metastases. BRAFV600E mutation was positive and chemotherapy included 12 courses of 5-fluorouracil, vemurafenib, irinotecan, and cetuximab. Complete response with recession of metastases was observed.Conclusion: The combination of fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor may have synergistic action, leading to recession of secondary metastases in patients with BRAFV600E-mutated colorectal cancer. Keywords: mCRC, BRAFV600E mutation, fluorouracil, vemurafenib, irinotecan, cetuximab
Xiaoyan Chen, Angang Wang
Published: 1 January 2019
OncoTargets and Therapy, Volume 12, pp 527-534; doi:10.2147/ott.s190108

Abstract:Clinical significance of miR-195 in hepatocellular carcinoma and its biological function in tumor progression Xiaoyan Chen,1 Angang Wang2 1Department of Laboratory Medicine, Women and Children’s Hospital of Linyi City, Shandong 276000, People’s Republic of China; 2Department of Laboratory Medicine, People’s Hospital of Yutai County, Shandong 272300, People’s Republic of China Background: Hepatocellular carcinoma (HCC) is one of the most lethal cancer types all over the world. Chronic viral hepatitis B and hepatitis C are risk factors that are associated with the development of HCC. The aim of this study is to identify the diagnostic role of serum miR-195 in HCC.Patients and methods: The expression levels of miR-195 were detected in 120 HCC patients, 64 hepatitis only patients, and 118 healthy control as well as 4 HCC cell lines, by using quantitative real-time PCR. The association of miR-195 with clinicopathological parameters of patients was analyzed with the chi-squared test. The receiver operating characteristic (ROC) curve was adopted to estimate the potential diagnostic value of miR-195. The cell experiments were carried out to verify the functional role of miR-195.Results: The expression of miR-195 was downregulated in HCC cells and serum of patients compared to the controls (all P<0.05). The miR-195 expression was associated with lymph node metastasis and TNM stage. The ROC curve analysis showed that miR-195 may be a noninvasive diagnostic marker for patients. By using miR-195 mimic or inhibitor, cell proliferation, migration, and invasion were inhibited by miR-195 overexpression but promoted by reduced expression of miR-195.Conclusion: The downregulation of miR-195 may serve as a novel diagnostic biomarker for differentiating HCC patients, healthy individuals, and hepatitis patients, and may involve in the tumor progression of HCC. Keywords: miRNA-195, diagnosis, proliferation, migration, invasion, hepatocellular carcinoma
Page of 350
Articles per Page
by